Spero Therapeutics(US:SPRO)2025-11-13 22:18Financial Performance - Spero reported a net loss of $7.4 million for Q3 2025, a significant improvement compared to a net loss of $17.1 million in Q3 2024, resulting in a diluted net loss per share of $0.13 versus $0.32[13]. - Total revenue for Q3 2025 was $5.4 million, down from $13.5 million in Q3 2024, primarily due to decreased collaboration revenue with GSK and a decline in grant revenue[13]. - General and administrative expenses for Q3 2025 were $4.2 million, down from $5.2 million in Q3 2024, mainly due to reduced personnel-related costs[13]. - Total operating expenses for Q3 2025 were $13.4 million, compared to $32.1 million in Q3 2024, reflecting a significant reduction in costs[19]. Research and Development - Research and development expenses decreased to $8.6 million in Q3 2025 from $26.9 million in Q3 2024, attributed to reduced clinical expenses related to the PIVOT-PO trial and lower costs for the SPR720 program[13]. - Spero has discontinued the SPR720 program in Q3 2025 after reviewing data from Phase 2a and Phase 1 trials[4]. Clinical Trials - The Phase 3 PIVOT-PO trial for tebipenem HBr demonstrated a 58.5% overall success rate compared to 60.2% for intravenous imipenem-cilastatin, indicating non-inferiority[6]. - The PIVOT-PO trial was stopped early for efficacy in May 2025, highlighting the promising results of tebipenem HBr[6]. - Tebipenem HBr is being developed as an oral treatment for complicated urinary tract infections (cUTI) and could provide an alternative to IV therapies, with a potential FDA filing planned for Q4 2025[2][5]. Cash Position - As of September 30, 2025, Spero had cash and cash equivalents of $48.6 million, which is expected to fund operations into 2028[13].